MY197663A - Pharmaceutical formulation - Google Patents
Pharmaceutical formulationInfo
- Publication number
- MY197663A MY197663A MYPI2018002103A MYPI2018002103A MY197663A MY 197663 A MY197663 A MY 197663A MY PI2018002103 A MYPI2018002103 A MY PI2018002103A MY PI2018002103 A MYPI2018002103 A MY PI2018002103A MY 197663 A MY197663 A MY 197663A
- Authority
- MY
- Malaysia
- Prior art keywords
- phenyl
- pharmaceutical formulation
- oxoacetamide
- fluoropyrimidin
- pyrrol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1609222.3A GB201609222D0 (en) | 2016-05-25 | 2016-05-25 | Pharmaceutical formulation |
| PCT/GB2017/051494 WO2017203270A1 (en) | 2016-05-25 | 2017-05-25 | Pharmaceutical formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY197663A true MY197663A (en) | 2023-06-30 |
Family
ID=56369959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2018002103A MY197663A (en) | 2016-05-25 | 2017-05-25 | Pharmaceutical formulation |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10973821B2 (OSRAM) |
| EP (1) | EP3463365B1 (OSRAM) |
| JP (1) | JP7141108B2 (OSRAM) |
| KR (1) | KR102464150B1 (OSRAM) |
| CN (1) | CN109982704B (OSRAM) |
| AU (1) | AU2017270942B2 (OSRAM) |
| CA (1) | CA3024771A1 (OSRAM) |
| CY (1) | CY1124733T1 (OSRAM) |
| DK (1) | DK3463365T3 (OSRAM) |
| ES (1) | ES2888951T3 (OSRAM) |
| GB (1) | GB201609222D0 (OSRAM) |
| HR (1) | HRP20211795T1 (OSRAM) |
| HU (1) | HUE056129T2 (OSRAM) |
| IL (1) | IL263167B (OSRAM) |
| LT (1) | LT3463365T (OSRAM) |
| MA (1) | MA45126A (OSRAM) |
| MX (1) | MX382199B (OSRAM) |
| MY (1) | MY197663A (OSRAM) |
| PL (1) | PL3463365T3 (OSRAM) |
| PT (1) | PT3463365T (OSRAM) |
| RU (1) | RU2760681C2 (OSRAM) |
| SG (1) | SG11201810323RA (OSRAM) |
| SI (1) | SI3463365T1 (OSRAM) |
| WO (1) | WO2017203270A1 (OSRAM) |
| ZA (1) | ZA201807851B (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201609222D0 (en) * | 2016-05-25 | 2016-07-06 | F2G Ltd | Pharmaceutical formulation |
| US11819503B2 (en) | 2019-04-23 | 2023-11-21 | F2G Ltd | Method of treating coccidioides infection |
| US20230338294A1 (en) * | 2020-04-26 | 2023-10-26 | Apollomics Inc. | Novel pharmaceutical formulation for c-met inhibitor |
| CN113429396A (zh) * | 2021-06-08 | 2021-09-24 | 深圳市祥根生物医药有限公司 | 一种五元杂芳环衍生物及其制备方法和用途 |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1051723A (OSRAM) | 1962-04-27 | |||
| US3202654A (en) | 1962-04-27 | 1965-08-24 | Bristol Myers Co | 6-[alpha-hydroxy-and alpha-amino-alpha-pyrrolylacetamido] penicillanic acids and salts thereof |
| US3252970A (en) | 1963-02-27 | 1966-05-24 | Ciba Geigy Corp | Aromatization |
| BE631632A (OSRAM) | 1963-04-26 | |||
| US3268558A (en) | 1964-11-05 | 1966-08-23 | Ortho Pharma Corp | 1-r-2, 4-dinitropyrroles |
| US3458515A (en) | 1966-07-21 | 1969-07-29 | American Home Prod | Piperazine substituted pyrroles |
| GB1208014A (en) | 1967-03-23 | 1970-10-07 | Glaxo Lab Ltd | Cephalosporins |
| US3573294A (en) | 1968-03-14 | 1971-03-30 | Glaxo Lab Ltd | 7 - (arylglyoxamido)cephalosporanic acids and their salts and alpha-carbonyl derivatives |
| BE790747A (fr) | 1971-10-30 | 1973-02-15 | Whitefin Holding Sa | Stereo-isomeres du 1-(1'-(0-chloro-benzyl)-pyrrol-2'-yl) -2-dibutyl sec.-amino-ethanol et procede pour leur preparation |
| GB1476503A (en) | 1973-06-21 | 1977-06-16 | Sterling Drug Inc | 1-arylamino-and 1-arylimino-pyrroles and preparation thereof |
| BE848465A (fr) | 1976-11-18 | 1977-03-16 | Stereo-isomeres de 1-(1'-benzyl-2' pyrryl)-2-disec.butylaminoethanols a activite analgesique et preparations pharmaceutiques qui les contiennent | |
| US4316900A (en) | 1977-10-05 | 1982-02-23 | Ciba-Geigy Corporation | Piperazinopyrrolobenzodiazepines |
| JPS57142966A (en) | 1981-02-27 | 1982-09-03 | Sagami Chem Res Center | (1-alkyl-2-pyrrolyl)glyoxylic acid amide derivative |
| JPS57144255A (en) | 1981-03-03 | 1982-09-06 | Sagami Chem Res Center | Alpha-methylthio(1-alkyl-2-pyrrolyl)acetamide derivative |
| US4761424A (en) | 1985-10-01 | 1988-08-02 | Warner-Lambert Company | Enolamides, pharmaceutical compositions and methods for treating inflammation |
| FR2601368B1 (fr) | 1986-07-08 | 1989-04-07 | Synthelabo | Derives de nitrofuranne, leur preparation et leur application en therapeutique. |
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| US5637592A (en) | 1994-07-12 | 1997-06-10 | Janssen Pharmaceutica N.V. | Acyl derivatives of azolones |
| CA2195570A1 (en) | 1994-07-21 | 1996-02-08 | Robert Delane Dillard | Indolizine spla2 inhibitors |
| KR19990008109A (ko) | 1995-04-28 | 1999-01-25 | 나가사까 겐지로 | 1,4-이치환 피페리딘 유도체 |
| EP0747756B1 (en) | 1995-06-06 | 2000-05-24 | Agfa-Gevaert N.V. | Photographic materials |
| JPH09249669A (ja) | 1996-03-13 | 1997-09-22 | Ono Pharmaceut Co Ltd | 縮合ピロール誘導体、およびそれらを有効成分として含有する薬剤 |
| PT986403E (pt) | 1997-06-13 | 2004-04-30 | Cydex Inc | Composicao com um tempo de vida de armazenagem prolongado compreendendo a ciclodextrina e drogas ou prodrogas que se decompoem em compostos insoluveis em agua |
| DE69837903T2 (de) | 1997-08-11 | 2008-02-14 | Pfizer Products Inc., Groton | Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit |
| US6331537B1 (en) | 1998-06-03 | 2001-12-18 | Gpi Nil Holdings, Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
| WO1999062881A1 (en) | 1998-06-03 | 1999-12-09 | Gpi Nil Holdings, Inc. | Aza-heterocyclic compounds used to treat neurological disorders and hair loss |
| EP1027887B1 (en) | 1999-02-10 | 2008-08-13 | Pfizer Products Inc. | Matrix controlled release device |
| MXPA01011117A (es) | 1999-05-04 | 2002-06-04 | Janssen Pharmaceutica Nv | Eteres antifungicos. |
| AU6438800A (en) | 1999-07-30 | 2001-02-19 | Norbert Heske | Cannula system for introducing endoscopic tools in a human or animal body |
| CZ20022047A3 (cs) | 1999-12-23 | 2003-09-17 | Pfizer Products Inc. | Farmaceutické kompozice poskytující zvýšenou koncentraci léčiva |
| GB0011089D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | Gastrin and cholecystokinin receptor ligands (11) |
| US7202239B2 (en) | 2001-04-12 | 2007-04-10 | Wyeth | Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists |
| US6825201B2 (en) | 2001-04-25 | 2004-11-30 | Bristol-Myers Squibb Company | Indole, azaindole and related heterocyclic amidopiperazine derivatives |
| EP1399442B1 (en) | 2001-06-06 | 2006-08-09 | Vertex Pharmaceuticals Incorporated | Cak inhibitors and uses thereof |
| ES2389027T3 (es) | 2001-06-20 | 2012-10-22 | Daiichi Sankyo Company, Limited | Derivados de diamina |
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| JP4865989B2 (ja) | 2002-02-01 | 2012-02-01 | ベンド・リサーチ・インコーポレーテッド | 改良された噴霧乾燥装置を使用する均質な噴霧乾燥された固体の非晶質薬物分散物を製造する方法 |
| BR0307515A (pt) | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão |
| US20040162298A1 (en) | 2002-02-23 | 2004-08-19 | Hsu-Tso Ho | Method of treating HIV infection by preventing interaction of CD4 and gp120 |
| KR20060021278A (ko) | 2002-08-15 | 2006-03-07 | 윤킹 리우 | 고체 나노미터 의약 및 이의 제조방법 |
| US20050032871A1 (en) | 2002-09-03 | 2005-02-10 | Sugen, Inc. | Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors |
| WO2004082606A2 (en) | 2003-03-13 | 2004-09-30 | Synta Pharmaceuticals Corp. | Fused pyrrole compounds |
| FR2854079B1 (fr) | 2003-04-25 | 2007-11-30 | Pf Medicament | Procede de preparation de complexes moleculaires |
| CL2004001884A1 (es) | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
| BRPI0415773A (pt) | 2003-10-24 | 2006-12-26 | Schering Ag | derivados de indolinona e sua aplicação no tratamento de estados de doença tais como cáncer |
| EP1753402B1 (en) | 2004-05-28 | 2008-10-01 | Pfizer Products Incorporated | Pharmaceutical compositions with enhanced performance comprising a hpmca polymer |
| US20060058286A1 (en) | 2004-09-16 | 2006-03-16 | Mark Krystal | Methods of treating HIV infection |
| WO2006082518A1 (en) | 2005-02-03 | 2006-08-10 | Pfizer Products Inc. | Pharmaceutical compositions with enhanced performance |
| US7842810B2 (en) | 2005-03-31 | 2010-11-30 | Janssen Pharmaceutica, Nv | Bicyclic pyrazole compounds as antibacterial agents |
| AR053713A1 (es) | 2005-04-20 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos heterociclicos y sus usos como agentes terapeuticos |
| US8486962B2 (en) | 2005-05-18 | 2013-07-16 | F2G Ltd. | Antifungal agents |
| US20090176837A1 (en) | 2005-07-12 | 2009-07-09 | Sony Corporation | Compounds with activity at retinoic acid receptors |
| WO2007015866A2 (en) | 2005-07-20 | 2007-02-08 | Kalypsys, Inc. | Inhibitors of p38 kinase and methods of treating inflammatory disorders |
| NZ571934A (en) | 2006-03-20 | 2012-05-25 | Vertex Pharma | Methods of spray drying formulations of vx-950 (telaprevir) |
| US8343548B2 (en) | 2006-08-08 | 2013-01-01 | Shin-Etsu Chemical Co., Ltd. | Solid dosage form comprising solid dispersion |
| US20080118500A1 (en) | 2006-11-16 | 2008-05-22 | Taiwan Liposome Company | Sustained releasing composition via local injection for treating eye diseases |
| GB0623209D0 (en) | 2006-11-21 | 2007-01-03 | F2G Ltd | Antifungal agents |
| CN101622302B (zh) | 2007-01-26 | 2013-01-23 | Isp投资公司 | 生产喷雾干燥产品的制剂工艺方法 |
| CN101260086B (zh) | 2007-03-06 | 2011-08-10 | 中国科学院上海药物研究所 | 蛋白酪氨酸磷酸酯酶1b抑制剂及其制备方法和用途 |
| GB0710121D0 (en) | 2007-05-25 | 2007-07-04 | F2G Ltd | Antifungal agents |
| US20100215747A1 (en) | 2007-07-13 | 2010-08-26 | Corey Jay Bloom | Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers |
| EP2626361B1 (en) * | 2008-04-24 | 2014-10-15 | F2G Limited | Pyrrole antifungal agents |
| GB0809773D0 (en) | 2008-05-29 | 2008-07-09 | F2G Ltd | Antifungal combination therapy |
| US20100093872A1 (en) | 2008-10-15 | 2010-04-15 | Erimos Pharmaceuticals Llc | Stable aqueous formulations of water insoluble or poorly soluble drugs |
| US20120196919A1 (en) | 2009-04-28 | 2012-08-02 | New York University | Ex-vivo treatment of immunological disorders with pkc-theta inhibitors |
| EP2579896B1 (en) | 2010-06-14 | 2016-07-20 | Dow Global Technologies LLC | Hydroxypropyl methyl cellulose acetate succinate with enhanced acetate and succinate substitution |
| WO2012031129A2 (en) | 2010-09-03 | 2012-03-08 | Bend Research, Inc. | Spray-drying apparatus and methods of using the same |
| JPWO2012060448A1 (ja) | 2010-11-05 | 2014-05-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗真菌剤としての併用医薬組成物 |
| US20120308662A1 (en) | 2011-06-01 | 2012-12-06 | Nitto Denko Corporation | Particulate preparation and method for producing the same |
| CA2852716C (en) | 2011-11-29 | 2015-11-17 | Jurox Pty Ltd | Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug |
| WO2013154607A1 (en) | 2012-04-11 | 2013-10-17 | Dow Global Technologies Llc | Esterified cellulose ethers having a specific substituent distribution |
| CN104736572B (zh) | 2012-08-24 | 2017-09-05 | 陶氏环球技术有限责任公司 | 部分交联的酯化纤维素醚 |
| JP6215945B2 (ja) | 2012-08-24 | 2017-10-18 | ダウ グローバル テクノロジーズ エルエルシー | 新規ヒドロキシアルキルメチルセルロースアセテートサクシネート |
| AU2014210103B2 (en) | 2013-01-22 | 2018-09-06 | F. Hoffmann-La Roche Ag | Pharmaceutical composition with improved bioavailability |
| WO2015007759A1 (en) | 2013-07-19 | 2015-01-22 | Boehringer Ingelheim Vetmedica Gmbh | Etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
| HRP20251029T1 (hr) | 2013-07-19 | 2025-10-24 | Boehringer Ingelheim Vetmedica Gmbh | Konzervirani eterificirani derivati ciklodekstrina koji sadrže tekući vodeni farmaceutski pripravak |
| KR20160093611A (ko) | 2013-12-05 | 2016-08-08 | 알라이즈 바이오시스템즈 게엠베하 | 경구 투여를 위한 약물 제제의 제조 방법 |
| PT107568B (pt) | 2014-03-31 | 2018-11-05 | Hovione Farm S A | Processo de secagem por atomização para a produção de pós com propriedades melhoradas. |
| LT3221308T (lt) | 2014-11-21 | 2018-12-27 | F2G Limited | Priešgrybeliniai agentai |
| GB201609222D0 (en) * | 2016-05-25 | 2016-07-06 | F2G Ltd | Pharmaceutical formulation |
-
2016
- 2016-05-25 GB GBGB1609222.3A patent/GB201609222D0/en not_active Ceased
-
2017
- 2017-05-25 HU HUE17728590A patent/HUE056129T2/hu unknown
- 2017-05-25 SG SG11201810323RA patent/SG11201810323RA/en unknown
- 2017-05-25 AU AU2017270942A patent/AU2017270942B2/en active Active
- 2017-05-25 JP JP2018561686A patent/JP7141108B2/ja active Active
- 2017-05-25 HR HRP20211795TT patent/HRP20211795T1/hr unknown
- 2017-05-25 ES ES17728590T patent/ES2888951T3/es active Active
- 2017-05-25 PL PL17728590T patent/PL3463365T3/pl unknown
- 2017-05-25 WO PCT/GB2017/051494 patent/WO2017203270A1/en not_active Ceased
- 2017-05-25 PT PT177285905T patent/PT3463365T/pt unknown
- 2017-05-25 MX MX2018014232A patent/MX382199B/es unknown
- 2017-05-25 DK DK17728590.5T patent/DK3463365T3/da active
- 2017-05-25 LT LTEPPCT/GB2017/051494T patent/LT3463365T/lt unknown
- 2017-05-25 US US16/303,999 patent/US10973821B2/en active Active
- 2017-05-25 CN CN201780046136.8A patent/CN109982704B/zh active Active
- 2017-05-25 SI SI201730974T patent/SI3463365T1/sl unknown
- 2017-05-25 RU RU2018142381A patent/RU2760681C2/ru active
- 2017-05-25 IL IL263167A patent/IL263167B/en unknown
- 2017-05-25 CA CA3024771A patent/CA3024771A1/en active Pending
- 2017-05-25 MY MYPI2018002103A patent/MY197663A/en unknown
- 2017-05-25 KR KR1020187037061A patent/KR102464150B1/ko active Active
- 2017-05-25 MA MA045126A patent/MA45126A/fr unknown
- 2017-05-25 EP EP17728590.5A patent/EP3463365B1/en active Active
-
2018
- 2018-11-21 ZA ZA2018/07851A patent/ZA201807851B/en unknown
-
2021
- 2021-03-01 US US17/189,091 patent/US20210186967A1/en not_active Abandoned
- 2021-11-19 CY CY20211101000T patent/CY1124733T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252368B (en) | 2-(5,1-dimethyl-3-phenyl-h1-pyrrol-2-yl)-n-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2- Oxacetamide and pharmaceutical preparations containing it | |
| PH12018501920A1 (en) | Bromodomain inhibitors | |
| GEP20186892B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| PH12016501310B1 (en) | Pharmaceutical compositions comprising azd9291 | |
| MY192084A (en) | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof | |
| PH12016501355B1 (en) | Bicyclic heterocyclic derivatives as bromodomain inhibitors | |
| NZ733135A (en) | Fused pyrimidine compounds for the treatment of hiv | |
| EP4286372A3 (en) | Pyrimidinones as factor xia inhibitors | |
| MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
| MX2016012573A (es) | Compuestos de dihidropirimidina y su aplicacion en productos farmaceuticos. | |
| PH12013502277A1 (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4 methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids | |
| CY1124733T1 (el) | Antimykhtiaσιko φαρμακευτικο σκευασμα | |
| MX2020001717A (es) | Inhibidores macrociclicos de mcl-1 y metodos de uso. | |
| SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
| MX2018005041A (es) | Compuestos para tratar la esclerosis lateral amiotrofica. | |
| MX2020011478A (es) | Formas solidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il) -1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida y sus composiciones farmaceuticas y usos. | |
| GEP20186938B (en) | Indolizine derivatives as phoshoinositide 3-kinases inhibitors | |
| BR112017004673A2 (pt) | formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida | |
| PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
| ZA201807446B (en) | Improved drug formulations | |
| MX2019015177A (es) | Formulaciones farmaceuticas de n-(2-(2-(dimetilamino)etoxi)-4-meto xi-5((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilam ida y las sales de ellas. | |
| ZA202203107B (en) | Azaindole carboxamide compounds for the treatment of mycobacterial infections | |
| MX359556B (es) | Acido 2-[5-[n-(4-fluorofenil)carbamoíl]pirimidin-2-ilsulfanilmetil ]-4-(trifluorometoxi)fenil]borónico. | |
| PH12018502668A1 (en) | Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof | |
| MX2015012153A (es) | Inhibidores de la quinasa pirrolopirimidina cdk9. |